Cisplatin ototoxicity in children: a practical grading system - PubMed (original) (raw)
Cisplatin ototoxicity in children: a practical grading system
P R Brock et al. Med Pediatr Oncol. 1991.
Abstract
A long-term follow-up study was carried out to assess ototoxicity in children who had been treated for a malignant tumour with "standard dose" cisplatin (60-100 mg/m2 per course), and were at least 2 years from stopping treatment. The median age at diagnosis was 2 years 2 months (range 1 month to 13.5 years). On the basis of hearing assessment by pure-tone audiometry, a practical grading system of hearing loss from 0 to 4 is proposed. Moderate to severe high-frequency hearing loss (grade 2-4) was found in half the children and 10 require appropriate hearing aids. The risk of developing ototoxicity increased significantly with the cumulative cisplatin dose (P = 0.027), although there was considerable individual susceptibility. Serial follow-up testing, to a median of 4 years after completion of cisplatin treatment, showed no recovery of hearing in any of these children. We suggest careful monitoring of young children by a consultant audiological physician throughout treatment with cisplatin, particularly when doses of 400 mg/m2 and over have been reached. Alternative chemotherapy should be discussed if grade 2 ototoxicity develops.
Similar articles
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
Li Y, Womer RB, Silber JH. Li Y, et al. Eur J Cancer. 2004 Nov;40(16):2445-51. doi: 10.1016/j.ejca.2003.08.009. Eur J Cancer. 2004. PMID: 15519518 - Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Bertolini P, et al. J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55. J Pediatr Hematol Oncol. 2004. PMID: 15454836 - Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM. Weissenstein A, et al. Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131-6. doi: 10.1016/j.ijporl.2011.10.020. Epub 2011 Nov 21. Int J Pediatr Otorhinolaryngol. 2012. PMID: 22104469 - Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW, Chinosornvatana N. Chang KW, et al. J Clin Oncol. 2010 Apr 1;28(10):1788-95. doi: 10.1200/JCO.2009.24.4228. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194861 Review. - Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2012 May 16;(5):CD009219. doi: 10.1002/14651858.CD009219.pub2. Cochrane Database Syst Rev. 2012. PMID: 22592737 Updated. Review.
Cited by
- Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study.
Troschel FM, Steike DR, Roers J, Kittel C, Siats J, Parfitt R, Hesping AE, Am Zehnhoff-Dinnesen A, Neumann K, Eich HT, Scobioala S. Troschel FM, et al. Strahlenther Onkol. 2024 Oct 25. doi: 10.1007/s00066-024-02308-5. Online ahead of print. Strahlenther Onkol. 2024. PMID: 39455453 - Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431.
Orgel E, Knight KR, Villaluna D, Krailo M, Esbenshade AJ, Sung L, Freyer DR. Orgel E, et al. Pediatr Blood Cancer. 2023 Jul 7:e30550. doi: 10.1002/pbc.30550. Online ahead of print. Pediatr Blood Cancer. 2023. PMID: 37416942 - Radiotherapy-associated Sensorineural Hearing Loss in Pediatric Oncology Patients.
Aslam MA, Ahmad H, Malik HS, Uinarni H, Karim YS, Akhmedov YM, Abdelbasset WK, Awadh SA, Abid MK, Mustafa YF, Farhood B, Sahebkar A. Aslam MA, et al. Curr Med Chem. 2024;31(33):5351-5369. doi: 10.2174/0929867330666230515112245. Curr Med Chem. 2024. PMID: 37190814 Review. - Special considerations in the design and implementation of pediatric otoprotection trials.
Freyer DR, Orgel E, Knight K, Krailo M. Freyer DR, et al. J Cancer Surviv. 2023 Feb;17(1):4-16. doi: 10.1007/s11764-022-01312-x. Epub 2023 Jan 13. J Cancer Surviv. 2023. PMID: 36637630 Review. - Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
Okada H, Kitagawa K. Okada H, et al. Cancer Med. 2023 Apr;12(7):7904-7910. doi: 10.1002/cam4.5565. Epub 2022 Dec 25. Cancer Med. 2023. PMID: 36567514 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources